Tenax Therapeutics Inc (TENX) - Net Assets
Based on the latest financial reports, Tenax Therapeutics Inc (TENX) has net assets worth $97.07 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($104.23 Million) and total liabilities ($7.16 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Tenax Therapeutics Inc tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $97.07 Million |
| % of Total Assets | 93.13% |
| Annual Growth Rate | N/A |
| 5-Year Change | 2186.89% |
| 10-Year Change | 466.31% |
| Growth Volatility | 248.38 |
Tenax Therapeutics Inc - Net Assets Trend (1995–2025)
This chart illustrates how Tenax Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See Tenax Therapeutics Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Tenax Therapeutics Inc (1995–2025)
The table below shows the annual net assets of Tenax Therapeutics Inc from 1995 to 2025. For live valuation and market cap data, see Tenax Therapeutics Inc market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $97.07 Million | +5.52% |
| 2024-12-31 | $91.99 Million | +1035.98% |
| 2023-12-31 | $8.10 Million | +442.50% |
| 2022-12-31 | $1.49 Million | -64.83% |
| 2021-12-31 | $4.24 Million | -8.23% |
| 2020-12-31 | $4.63 Million | +22.61% |
| 2019-12-31 | $3.77 Million | -67.95% |
| 2018-12-31 | $11.77 Million | +32.53% |
| 2017-12-31 | $8.88 Million | -48.18% |
| 2016-12-31 | $17.14 Million | -71.63% |
| 2015-12-31 | $60.42 Million | -27.10% |
| 2014-12-31 | $82.89 Million | 0.00% |
| 2013-12-31 | $82.89 Million | +173.54% |
| 2012-12-31 | $30.30 Million | +3577.00% |
| 2011-12-31 | $-871.46K | -140.97% |
| 2010-12-31 | $2.13 Million | -44.46% |
| 2009-12-31 | $3.83 Million | -42.00% |
| 2008-12-31 | $6.60 Million | +1540.87% |
| 2007-12-31 | $-458.25K | -346.08% |
| 2006-12-31 | $186.22K | -80.37% |
| 2005-12-31 | $948.40K | -34.50% |
| 2004-12-31 | $1.45 Million | +25.66% |
| 2003-12-31 | $1.15 Million | -6.77% |
| 2002-12-31 | $1.24 Million | -63.59% |
| 2001-12-31 | $3.39 Million | -42.02% |
| 2000-12-31 | $5.85 Million | +5954.21% |
| 1999-12-31 | $-100.00K | -128.45% |
| 1998-12-31 | $351.55K | +224.44% |
| 1997-12-31 | $-282.51K | +52.73% |
| 1996-12-31 | $-597.60K | 0.00% |
| 1995-12-31 | $-597.60K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tenax Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 36107724400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.00% |
| Other Components | $464.52 Million | 478.54% |
| Total Equity | $97.07 Million | 100.00% |
Tenax Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Tenax Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Parag Milk Foods Limited
NSE:PARAGMILK
|
$306.06 Million |
|
Shenzhen Capol International & Associates Co Ltd
SHE:002949
|
$306.09 Million |
|
High Liner Foods Incorporated
TO:HLF
|
$306.21 Million |
|
Sunplus Innovation Technology Inc.
TWO:5236
|
$306.25 Million |
|
Rana Gruber AS
OL:RANA
|
$305.95 Million |
|
Metropolis Healthcare Limited
NSE:METROPOLIS
|
$305.83 Million |
|
Arvind SmartSpaces Limited
NSE:ARVSMART
|
$305.78 Million |
|
Guangdong Yantang Dairy Co Ltd
SHE:002732
|
$305.78 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tenax Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 91,993,000 to 97,071,000, a change of 5,078,000 (5.5%).
- Net loss of 52,599,000 reduced equity.
- Other factors increased equity by 57,677,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-52.60 Million | -54.19% |
| Other Changes | $57.68 Million | +59.42% |
| Total Change | $- | 5.52% |
Book Value vs Market Value Analysis
This analysis compares Tenax Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.80x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1995-12-31 | $-199201.00 | $11.87 | x |
| 1996-12-31 | $-134292.81 | $11.87 | x |
| 1997-12-31 | $-63485.84 | $11.87 | x |
| 1998-12-31 | $67218.55 | $11.87 | x |
| 1999-12-31 | $-12500.00 | $11.87 | x |
| 2000-12-31 | $731776.38 | $11.87 | x |
| 2001-12-31 | $424311.13 | $11.87 | x |
| 2002-12-31 | $154480.13 | $11.87 | x |
| 2003-12-31 | $144029.25 | $11.87 | x |
| 2004-12-31 | $122188.10 | $11.87 | x |
| 2005-12-31 | $69378.27 | $11.87 | x |
| 2006-12-31 | $12931.67 | $11.87 | x |
| 2007-12-31 | $-31822.71 | $11.87 | x |
| 2008-12-31 | $366820.22 | $11.87 | x |
| 2009-12-31 | $116043.76 | $11.87 | x |
| 2010-12-31 | $59084.39 | $11.87 | x |
| 2011-12-31 | $-20098.34 | $11.87 | x |
| 2012-12-31 | $103571.12 | $11.87 | x |
| 2013-12-31 | $283310.64 | $11.87 | x |
| 2014-12-31 | $94402.46 | $11.87 | x |
| 2015-12-31 | $68864.01 | $11.87 | x |
| 2016-12-31 | $19506.27 | $11.87 | x |
| 2017-12-31 | $10074.13 | $11.87 | x |
| 2018-12-31 | $12865.06 | $11.87 | x |
| 2019-12-31 | $974.30 | $11.87 | x |
| 2020-12-31 | $997.96 | $11.87 | x |
| 2021-12-31 | $330.07 | $11.87 | x |
| 2022-12-31 | $81.17 | $11.87 | x |
| 2023-12-31 | $32.59 | $11.87 | x |
| 2024-12-31 | $6.02 | $11.87 | x |
| 2025-12-31 | $2.48 | $11.87 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tenax Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -54.19%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.07x
- Recent ROE (-54.19%) is above the historical average (-210.50%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1995 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.29 Million |
| 1996 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.29 Million |
| 1997 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.88 Million |
| 1998 | -227.56% | -80000000.00% | 0.00x | 2.80x | $-835.16K |
| 1999 | 0.00% | -91133900.00% | 0.00x | 0.00x | $-901.34K |
| 2000 | -28.56% | -167224200.00% | 0.00x | 1.06x | $-2.26 Million |
| 2001 | -49.26% | -167224200.00% | 0.00x | 1.12x | $-2.01 Million |
| 2002 | -282.22% | 0.00% | 0.00x | 1.07x | $-3.61 Million |
| 2003 | -193.31% | 0.00% | 0.00x | 1.29x | $-2.34 Million |
| 2004 | -155.34% | 0.00% | 0.00x | 1.25x | $-2.39 Million |
| 2005 | -281.82% | 0.00% | -0.02x | 1.33x | $-2.77 Million |
| 2006 | -1788.71% | 0.00% | -0.04x | 3.28x | $-3.35 Million |
| 2007 | 0.00% | 0.00% | -0.01x | 0.00x | $-3.29 Million |
| 2008 | -101.79% | 0.00% | 0.00x | 1.27x | $-7.38 Million |
| 2009 | -274.38% | -22174.01% | 0.01x | 1.31x | $-10.89 Million |
| 2010 | -491.21% | -3241.30% | 0.09x | 1.66x | $-10.66 Million |
| 2011 | 0.00% | -3785.81% | 0.07x | 0.00x | $-15.63 Million |
| 2012 | -64.49% | -6768.30% | 0.01x | 1.12x | $-22.57 Million |
| 2013 | -23.58% | -6768.30% | 0.00x | 1.13x | $-27.83 Million |
| 2014 | -16.99% | -28571.63% | 0.00x | 1.13x | $-22.37 Million |
| 2015 | -23.31% | -28571.63% | 0.00x | 1.21x | $-20.12 Million |
| 2016 | -256.25% | 0.00% | 0.00x | 1.36x | $-45.64 Million |
| 2017 | -99.53% | 0.00% | 0.00x | 1.11x | $-9.73 Million |
| 2018 | -57.88% | 0.00% | 0.00x | 1.13x | $-7.99 Million |
| 2019 | -222.51% | 0.00% | 0.00x | 1.69x | $-8.77 Million |
| 2020 | -212.98% | 0.00% | 0.00x | 1.48x | $-10.31 Million |
| 2021 | -765.06% | 0.00% | 0.00x | 1.41x | $-32.90 Million |
| 2022 | -740.11% | 0.00% | 0.00x | 2.28x | $-11.20 Million |
| 2023 | -95.22% | 0.00% | 0.00x | 1.44x | $-8.52 Million |
| 2024 | -19.13% | 0.00% | 0.00x | 1.05x | $-26.80 Million |
| 2025 | -54.19% | 0.00% | 0.00x | 1.07x | $-62.31 Million |
Industry Comparison
This section compares Tenax Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tenax Therapeutics Inc (TENX) | $97.07 Million | 0.00% | 0.07x | $305.96 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Tenax Therapeutics Inc
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imat… Read more